Silk Fibroin Nanoparticles for Enhanced Cuproptosis and Immunotherapy in Pancreatic Cancer Treatment
Advanced Science · 2025-05 · 12 (18)
DOI: 10.1002/advs.202417676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.03.2025. Verfasst von Si Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biliary-pancreatic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Fibroins, Nanoparticles, Immunotherapy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cuproptosis is a newly discovered copper ion‐dependent programmed cell death. Elesclomol (ES) is a Cu 2+ transporter that delivers Cu 2+ into tumor cells, causing cell death at toxic doses. However, ES has a short blood half‐life, limiting its accumulation in tumors. This study introduces Tussah silk fibroin nanoparticles (TSF@ES‐Cu NPs) to protect ES and Cu 2+ . TSF, with a stable structure, resists metabolism in circulation. Targeting tumors with natural RGD peptides and TSF's unique secondary structure, enhances drug enrichment and special release in pancreatic tumors, improving treatment efficacy. In vitro, TSF@ES‐Cu induces tumor cell cuproptosis, releases DAMPs, promotes dendritic cells (DCs) maturation, and macrophage M1 polarization. In vivo, TSF@ES‐Cu reshapes the tumor microenvironment (TME), increasing mature DCs from 22.7% to 43.3%, CD8 + T cells from 5.08% to 17.1%, and reducing M2 macrophages from 50.7% to 18.4%. Additionally, the combined anti‐tumor efficacy of TSF@ES‐Cu and αPDL‐1 is 1.6 times higher than TSF@ES‐Cu alone and 2.5 times higher than αPDL‐1 alone. In summary, this study reports that the combination of TSF@ES‐Cu and αPDL‐1 effectively induces cuproptosis and reshapes the TME, offering a new approach for copper nanomaterial‐based tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biliary-pancreatic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200020, China.
- Department of Pathology, Xinhua Hospital, Affiliated to Medicine School of Shanghai Jiaotong University, Shanghai, 200092, China.
- School of Stomatology, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010030, China.
- Department of Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
ORCID-Profile: Wei Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gao, S., Ge, H., Gao, L., Gao, Y., Tang, S., Li, Y., Yuan, Z., & Chen, W. (2025). Silk Fibroin Nanoparticles for Enhanced Cuproptosis and Immunotherapy in Pancreatic Cancer Treatment. Advanced Science, 12(18). https://doi.org/10.1002/advs.202417676
Vancouver
Gao S, Ge H, Gao L, Gao Y, Tang S, Li Y, et al. Silk Fibroin Nanoparticles for Enhanced Cuproptosis and Immunotherapy in Pancreatic Cancer Treatment. Advanced Science. 2025;12(18). doi:10.1002/advs.202417676
BibTeX
@article{Gao2025,
author = {Gao, Si and Ge, Haodong and Gao, Lili and Gao, Ying and Tang, Shuibin and Li, Yiming and Yuan, Zhiqing and Chen, Wei},
title = {Silk Fibroin Nanoparticles for Enhanced Cuproptosis and Immunotherapy in Pancreatic Cancer Treatment},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {18},
doi = {10.1002/advs.202417676}
}
EUVIMED